Vyteris to Pursue Development of Pain Medication Compounds
Vyteris has announced an initiative to identify and target candidate drugs in the pain management field that could potentially be delivered using the company’s active patch transdermal system.
Vyteris’s pain management initiative will examine several candidate drugs to improve their safety and efficacy profiles using the company’s proprietary controlled drug delivery technology and to potentially extend their patent protection.
The initiative will include efforts to secure joint development agreements with pharmaceutical manufacturers for in vitro and in vivo testing of pain medication compounds. Compounds under investigation for possible use include nonsteroidal anti-inflammatory drugs, opioids, narcotic analgesics and anaesthetic agents.
Haro Hartounian, president of Vyteris, said: “Our first successful FDA approval for our active patch transdermal system was for topical delivery of lidocaine, and we are now examining other drugs in pain management for use in our system as the next step in our market development.
“We believe the unique properties of several pain medications make them excellent candidates for testing and use with our system. We have proven the concept of transdermal delivery of pain medication using our system now we are looking to demonstrate that our system is versatile and can work with a variety of different drugs in the pain management area.”